

The Impact of Materials Sciences in Increasing Understanding of Drug Product Performance and Manufacturability

Fiona Clarke






Its All About Relationships



Materials Science will be the language of "reconciliation"








Bridging with Characterisation





FACE is the bridge between the world of API and DP, facilitated by material characteristics.

Equipment

Chemical Imaging / Spectroscopy

- •Near-infrared, Infrared, Raman and X-Ray Fluorescence Microscopes
- •Terahertz Imaging
- •Tablet Press
- •Microtome and Rapid Trim
- •X-Ray µTomography
- •Near-infrared, Raman and infrared spectroscopy

Physical Characterisation/ Surface Properties

- Malvern and Sympatec Laser Diffraction
- •Light Microscopes
- QicPic
- •G3
 - •Specific Surface Area
- •Kruss Tensiometer
- Surface Energy Analyser (IGC)
- Multi-Station Dynamic Vapor Sorption

Physico-Chemical / Crystallisation

- •Powder X-Ray Diffraction
- •Crystal 16
- •Thermal Gravimetric Analysis coupled with Mass Spectrometer
- Hyper and Heat Flux Differential Scanning Calorimetry
- Simultaneous Analyser coupled with infrared spectroscopy
- •Dynamic Mechanical Analyser

Particulate Matter

- •Light Microscope
- •Inverted light microscope
- •Infrared Microscope
- Scanning electron microscopy coupled with energy dispersive X-rays

Material Assessment

- •Kinexus Rheometer
- •Powder Rheometer
- •Ring Shear Tester
- •Helium Pycnometer
- •Air Jet Sieve
- •Compaction Simulator
- •Texture Analyser

Non-Solids

- Ultrasonics Spectroscopy
- Brightwell Image Analyser
- TurbiScan
- •ZetaSizer
- •Rheolaser

Chemical Comparability

- •Complete Orthagonal Method Evaluation (Liquid Chromatography)
- •Inductively Coupled Plasma-Optical Emission Spectroscopy
- •Nuclear Magnetic Resonance
- Structural Elucidation (through ARD)

Regularly Outsourced

- •Residual Solvents (GC)
- •Solid State NMR
- •Gel Permation Chromatography
- •Time of Flight –Secondary Ion Mass Spectrometry/X-Ray Photon Spectroscopy

Note: Equipment can be used in different work area, but one shown is where there has been greatest application


Technologies for Chemical Imaging





Matrix Elucidation


Near-Infrared Microscopy




























Mid-Infrared Microscopy













k-Ray Fluorescence Microscopy

X-Ray µTomography



Toolbox for Liquid and Suspension Formulations







Optical Microscopy

- Used to determine particle morphology
- Structural information by phase contrast microscopy




Sympatec Laser Diffraction

 Particle size for liquid dispersions with focused measurement range



Scanning Electron Microscopy

- Particulate matter or particle morphology
- Surface characteristics



Malvern Laser Diffraction

•Particle size for liquid dispersions with wide measurement range



Rheology



Image Analysis

•Optical particle sizing technique



Rheolaser



Turbiscan

•De-stabilisation of a network structure i.e. Sedimentation or creaming



Tensiometer

Wetability of powder beds for wet granulation and dissolution issues



Zeta-Sizer

- Zeta potential
- Sizing



Roots in Drug Product Characterisation

Using Chemical Images to Understand Product Performance







Matrix Elucidation Providing Insights into Slow Dissolution




Typical



Slow Disso



No differences in distribution of major components




Focuses Investigation Team of Raw Material Variation or Blending Operation


Excipient Variability



- CoA comparison of Raw Materials Identified no variations
- Characterisation Identified difference in hydration state of magnesium stearate
- Now known as a critical attribute for this product









Drug Product Issue – Blend Uniformity



- Flow issues during DP manufacture resulted in blend uniformity issues following an API source change.
 - API from new supplier had passed all specifications




Characterisation Studies identify new API has a greater proportion of fines (<10 µm) which results in different cohesion properties.



Supporting DP Trials




Trial Batch with New API Source



Inhomogeneity in Drug Product



- Following a site change inhomogeneity observed in drug product results.
- Processing equipment and parameters had been comparable.
- Raw materials all meet CoA.




Excipient Evaluation



- Full characterisation of 15+ components identified differences in particle size and chemical content of some raw materials
 - Issues linked to particle size differences
- Utilisation of raw materials from initial DP site gave rise to good homogeneity









Selecting Excipient for Ophthalmic Suspension







Excipient Identification



- Notified that current raw material supplier will be ceasing manufacture.
- Understanding of this material and its attributes in DP deemed a necessary for low risk change.
 - Material from 4 alternate suppliers sourced for comparison.







Assessing PSD Number Based Distribution Volume Based Distribution Alternate sources offer very different PSD from current source

Evaluation of Physico- Chemical Properties




 NIR and PXRD identify chemical variations in one alternative source, which by EGA is shown to be a anhydrous form.






Sample	% Mass lost (30-145°C)
M Alternative	2.31
Current	0.83
P Alternative	0.77
F Alternative	0.60





Viscosity of Lab Scale Formulations





δ Phase Angle G' Elastic Modulus G" Viscous Modulus










Suspension Properties







Variation in Settled Bed Height









Pfizer GLOBAL SUPPLY



API Morphology








Size and Flow Attributes






Surface Properties Drive Sedimentation



 Issues lots have higher surface heterogeneity, which could be driving the stability of the suspension of the final drug product.





Variable Dissolution


A physical attribute










• Five capsule lots with variable dissolution performance



Only excipient with variation through characterisation testing was magnesium stearate







S1

NIR Chemical Images Identify No significant Variation

Looking at the Capsule Contents



X-ray images reveal variation in powder packing


OOS






Crude Classification of Powder State in Capsules (Compaction).








Understanding Dissolution Performance of Capsule Product




• To build understanding of prediction ability of X-ray images, a 'calibration set' was generated using different tamping pin settings.



Greyscale Histograms were generated from X-ray Images






Understanding Dissolution Performance of Capsule Product





A 2-class SIMCA model was created using low-pressure and high-pressure capsules.



Chemometrics and Classification Success











6 Rotational Angles used to represent a capsule.





High Pressure Plot

with greyscale histograms and chemometrics can be used to classify the performance of this product.

Low Pressure Plot



Solid State Characterisation for Understanding Impurity Levels







Question: Why are levels of 1 imp higher at one DP site? · ·




- Both sites use same API source
- Chemical Images reveal difference in one excipient.








Comparison of Excipient Properties












How does this impact Tablet Stability Performance? ...








Implemented Learnings





Building Learnings into Workflow for API-DP





Leveraging API-DP Interface



- By building understanding of material characteristics (be that API, excipients or drug product) understanding of product attributes are increased.
- Leveraging this knowledge in combination with that of API and Drug Product enables more robust drug products.
- It also enables low risk transfers and sourcing decisions.

